LifeMD (NASDAQ:LFMD) Stock Rating Upgraded by Wall Street Zen

LifeMD (NASDAQ:LFMD) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Other research analysts also recently issued research reports about the stock. B. Riley Financial dropped their price objective on shares of LifeMD from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of LifeMD in a research report on Monday, December 29th. BTIG Research reissued a “buy” rating and set a $10.00 price target on shares of LifeMD in a research note on Tuesday, March 10th. HC Wainwright raised their price target on LifeMD from $9.00 to $10.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of LifeMD in a report on Tuesday, March 10th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.86.

LifeMD Stock Performance

LFMD stock opened at $3.98 on Friday. The company’s fifty day moving average price is $3.33 and its 200-day moving average price is $4.51. LifeMD has a one year low of $2.56 and a one year high of $15.84. The company has a market capitalization of $190.92 million, a PE ratio of 15.31 and a beta of 1.92.

LifeMD (NASDAQ:LFMD) last posted its earnings results on Monday, March 9th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.03). The company had revenue of $46.87 million for the quarter, compared to analysts’ expectations of $48.57 million. LifeMD had a net margin of 6.58% and a negative return on equity of 83.93%. On average, research analysts predict that LifeMD will post -0.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in LFMD. Federated Hermes Inc. grew its position in LifeMD by 278.1% in the fourth quarter. Federated Hermes Inc. now owns 980,285 shares of the company’s stock worth $3,343,000 after acquiring an additional 721,018 shares in the last quarter. Prescott Group Capital Management L.L.C. purchased a new stake in LifeMD during the fourth quarter valued at approximately $2,344,000. Arrowstreet Capital Limited Partnership lifted its stake in shares of LifeMD by 1,767.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company’s stock valued at $5,924,000 after purchasing an additional 411,651 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of LifeMD by 581.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock valued at $5,619,000 after purchasing an additional 352,004 shares during the last quarter. Finally, Jump Financial LLC boosted its holdings in shares of LifeMD by 205.0% in the 2nd quarter. Jump Financial LLC now owns 515,052 shares of the company’s stock worth $7,015,000 after purchasing an additional 346,171 shares during the period. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.